I Continuing Review

A031702, A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) (Protocol Version Date 06/10/19)

II Continuing Review

A071701, Genomically-Guided Treatment Trial in Brain Metastases (Protocol Version Date 05/07/19)

III Continuing Review

CALGB-40503, Endocrine Therapy with or without ANTI-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer (Protocol Version Date 02/06/19)

IV Continuing Review

NRG-HN001, Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (Protocol Version Date 09/27/18)

V Continuing Review

S1007, A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical
Trial RX for Positive Node, Endocrine Responsive Breast Cancer  (Protocol Version Date 11/06/18)

VI  New Study - Initial Review

A081801, Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO  (Protocol Version Date 11/13/19)

VII  New Study - Initial Review

S1905, A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Actue Lymphoblastic Leukemia (T-ALL)  (Protocol Version Date 12/20/19)